Benitec Ltd (ASX:BLT), an Australian biotechnology company focused on gene silencing for human therapeutics is edging closer to a resolution on its long-running re-examination proceedings for an important platform technology patent.
Benitec Ltd (ASX:BLT) shares were up over by over 80% this morning after the US Patent and Trademark office’s board of Patent Appeals and Interferences reversed all of their previous rejections of the “Control of Gene Expression” patent.
Nufarm Limited (ASX:NUF) shares have dropped 6% today as the company cancels its FY2010 dividend, and renegotiates its banking covenants
Murchison Metals (ASX:MMX) has denied that there's any truth to rumors regarding the ongoing role Mitsubishi, its partner in the Jack Hills Iron ore project.
Murchison Metals (ASX:MMX) dropped as low as $1.51 today before announcing a trading halt, pending an announcement.
James Hardie (ASX:JHX) has lost a Federal Court of Australia appeal regarding a $330M tax charge
Investors have driven shares in energy giant Santos Ltd (ASX:STO) up over 15% in the last week as several media organisations speculated about potential billion dollar deals to sell part of its Gladstone coal-seam LNG project.
Beleaguered mobile security solution vendor, Nexbis (ASX:NBS) is still languishing near record lows after a difficult year.
Shares in Avexa Limited (ASX:AVX) have risen by over a third since the beginning of July.
Gartner Trims Worldwide IT Spending Growth Forecast to 3.9 Percent for 2010
Metcash Trading (ASX:MTS) buys 77 Franklins stores in $215M deal
A few painstaking steps offer numerous payoffs, including lowering risks associated with change, eliminating resource conflicts and redundancies, and learning from successes and mistakes of the past - all of which help to save money.
The ASX200 was down 77 points to 4268 at noon, a drop of 1.8%. The slump mirrors drops on Wall Street and European exchanges overnight.
Riversdale Mining (ASX:RIV) announces development deals for Zambeze Coal Project in Mozambique
Pharmaceutical company, Pharmaxis (ASX:PXS) underwhelmed the market with the results from their phase III clinical trial of cystic fibrosis treatment drug Bronchitol®.